Loading...
•
Jun 30, 2021
Castle Biosciences Q2 2021 Earnings Report
Reported revenues of $22.8 million and increased total dermatology test report volume by 70%.
Key Takeaways
Castle Biosciences reported strong Q2 2021 results with a 79% increase in revenue compared to Q2 2020. The company also saw a 70% increase in DecisionDx-Melanoma test reports and raised its 2021 revenue guidance to $89-93 million.
Revenues were $22.8 million, a 79% increase compared to $12.7 million during the same period in 2020.
Total gene expression profile test reports delivered in the second quarter of 2021 were 7,007, compared to 3,314 in the same period of 2020.
DecisionDx-Melanoma test reports delivered in the second quarter of 2021 were 5,128, compared to 3,008 in the second quarter of 2020, an increase of 70%.
The company is raising 2021 revenue guidance to $89-93 million from $80-83 million.
Forward Guidance
Castle Biosciences is increasing its previously issued guidance for anticipated total revenue in 2021. The Company now anticipates generating $89-93 million in total revenue in 2021, compared to the previously provided guidance of $80-83 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...